לברסט

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

LETROZOLE 2.5 MG

Available from:

RAFA LABORATORIES LTD

ATC code:

L02BG04

Pharmaceutical form:

FILM COATED TABLETS

Administration route:

PER OS

Manufactured by:

SIEGFRIED GENERICS ( MALTA) LTD

Therapeutic group:

LETROZOLE

Therapeutic indications:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Authorization date:

2012-04-01